Search research articles
Contact Us
Filters
Showing results (71-80 of 112) with videos related to
Page
of 12
Sort By:
The Lancet. Oncology
|
November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
Edward S Kim, Marcus Neubauer, Allen Cohn, et al.
The Oncologist
|
June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
The Oncologist
|
March 13, 2020
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
Lee Schwartzberg, Rudolph Navari, Rebecca Clark-Snow, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2008
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
Ann M Mauer, Ezra E W Cohen, Patrick C Ma, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 26, 2016
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, et al.
British Journal of Haematology
|
March 29, 2014
Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
Lee Schwartzberg, Robert Hermann, Ian Flinn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 6, 2020
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy
Eric J Roeland, Kathryn J Ruddy, Thomas W LeBlanc, et al.
JCO Precision Oncology
|
September 11, 2020
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
Hatem Soliman, Darl D Flake, Anthony Magliocco, et al.
Future Oncology (London, England)
|
June 15, 2023
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA
Lee Schwartzberg, Davey Daniel, Daniel Vaena, et al.
Annals of Surgical Oncology
|
January 8, 2020
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Hatem Soliman, Susanne Wagner, Darl D Flake, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 112) with videos related to
Sort By:
Page
of 12
The Lancet. Oncology
|
November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
Edward S Kim, Marcus Neubauer, Allen Cohn, et al.
The Oncologist
|
June 15, 2022
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Bolivar Arboleda, Rupert Bartsch, Evandro de Azambuja, et al.
The Oncologist
|
March 13, 2020
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
Lee Schwartzberg, Rudolph Navari, Rebecca Clark-Snow, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2008
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
Ann M Mauer, Ezra E W Cohen, Patrick C Ma, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
November 26, 2016
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, et al.
British Journal of Haematology
|
March 29, 2014
Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma
Lee Schwartzberg, Robert Hermann, Ian Flinn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 6, 2020
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy
Eric J Roeland, Kathryn J Ruddy, Thomas W LeBlanc, et al.
JCO Precision Oncology
|
September 11, 2020
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
Hatem Soliman, Darl D Flake, Anthony Magliocco, et al.
Future Oncology (London, England)
|
June 15, 2023
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA
Lee Schwartzberg, Davey Daniel, Daniel Vaena, et al.
Annals of Surgical Oncology
|
January 8, 2020
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Hatem Soliman, Susanne Wagner, Darl D Flake, et al.
Page
of 12